[Pneumonia, pneumocystis pneumonia].
Pneumonia (almost equally bacterial) is the most common and serious adverse events of the patients with rheumatoid arthritis (RA) prescribing anti-tumor necrosis factor(TNF) agents. Furthermore, it has been shown that Pneumocystis jirovecii should be one of the important causal microorganisms by the results of postparketing all-patients registration surveillance in Japan. Older age, pulmonary comorbidities, diabetes mellitus, or dosage of co -prescribing glucocorticoid has been extracted as a predictable risk factor respectively and synergistically by the surveillance. When prescribing anti-TNF agents, it is possible that considering these risk factors might reduce the incidence of bacterial or Pneumocystis pneumonia in RA patients.
Koike
Ryuji
R
Clinical Research Center, Tokyo Medical and Dental University.
Harigai
Masayoshi
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D045363:Pneumocystis carinii; D018410:Pneumonia, Bacterial / Q000453:epidemiology / Q000209:etiology*; D011020:Pneumonia, Pneumocystis / Q000453:epidemiology / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept